AR095594A1 - Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos - Google Patents

Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos

Info

Publication number
AR095594A1
AR095594A1 ARP140101219A ARP140101219A AR095594A1 AR 095594 A1 AR095594 A1 AR 095594A1 AR P140101219 A ARP140101219 A AR P140101219A AR P140101219 A ARP140101219 A AR P140101219A AR 095594 A1 AR095594 A1 AR 095594A1
Authority
AR
Argentina
Prior art keywords
overweight
antibiotics
methods
patients
obesos
Prior art date
Application number
ARP140101219A
Other languages
English (en)
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51581190&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR095594(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of AR095594A1 publication Critical patent/AR095594A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere de manera general a métodos para tratar infecciones en pacientes con sobrepeso u obesos usando antibióticos. Reivindicación 40: El método de la reivindicación 39, donde el compuesto es delafloxacina. Reivindicación 41: El método de cualquiera de las reivindicaciones anteriores, donde la dosificación está comprendida entre aproximadamente 10 mg/día y aproximadamente 600 mg/día.
ARP140101219A 2013-03-15 2014-03-17 Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos AR095594A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361790179P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095594A1 true AR095594A1 (es) 2015-10-28

Family

ID=51581190

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101219A AR095594A1 (es) 2013-03-15 2014-03-17 Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos

Country Status (14)

Country Link
US (3) US12036219B2 (es)
EP (1) EP2969004A4 (es)
JP (2) JP6617097B2 (es)
KR (1) KR102237887B1 (es)
AR (1) AR095594A1 (es)
AU (2) AU2014239965A1 (es)
BR (1) BR112015023044A8 (es)
CA (1) CA2904387C (es)
CL (1) CL2015002759A1 (es)
HK (1) HK1219690A1 (es)
IL (1) IL241113A0 (es)
MX (1) MX2015011760A (es)
TW (1) TWI641372B (es)
WO (1) WO2014152332A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201605447A (zh) * 2014-06-20 2016-02-16 美林塔治療學有限公司 處理感染的方法
WO2016137806A2 (en) 2015-02-23 2016-09-01 Theravance Biopharma Antibiotics Ip, Llc Doses and methods of administering telavancin
CN107216353B (zh) * 2016-03-21 2020-05-19 山东诚创医药技术开发有限公司 一种头孢洛林酯咪唑盐的精制方法
JP2019527214A (ja) 2016-07-14 2019-09-26 アカオジェン インコーポレイテッド 細菌感染症の処置における使用のためのセフチブテンとクラブラン酸の組み合わせ

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO156828C (no) 1980-11-10 1987-12-02 Otsuka Pharma Co Ltd Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser.
DK170473B1 (da) 1985-06-20 1995-09-11 Daiichi Seiyaku Co S(-)-pyridobenzoxazinforbindelser
JPH089597B2 (ja) 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
CA1315229C (en) 1987-06-10 1993-03-30 Patrick J. Baker Chromatographic purification process
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
ATE146783T1 (de) 1991-11-01 1997-01-15 Upjohn Co Substituierte aryl- und heteroaryl- phenyloxazolidinone
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
MY128335A (en) 1994-01-28 2007-01-31 Lilly Co Eli Glycopeptide antibiotic derivatives
EP0688772B1 (en) 1994-06-16 1999-05-06 LG Chemical Limited Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituents and processes for their preparation
US5776944A (en) 1994-06-16 1998-07-07 Lg Chemical Ltd. 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof
KR100371723B1 (ko) 1994-08-12 2003-03-15 도야마 가가쿠 고교 가부시키가이샤 신규한퀴놀론-또는나프틸리돈-카복실산유도체또는그의염
JP3449658B2 (ja) 1994-12-21 2003-09-22 杏林製薬株式会社 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
CA2232728C (en) 1995-09-22 2003-11-04 Wakunaga Pharmaceutical Co., Ltd. Novel pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components
DE19546249A1 (de) 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
CA2242242C (en) 1996-02-09 2001-08-07 Toyama Chemical Co., Ltd. Quinolonecarboxylic acid derivatives or salts thereof
US5939382A (en) 1996-11-21 1999-08-17 Eli Lilly And Company Reducing agent for reductive alkylation of glycopeptide antibiotics
US5952466A (en) 1997-11-12 1999-09-14 Eli Lilly And Company Reductive alkylation of glycopeptide antibiotics
ID18900A (id) 1996-11-21 1998-05-20 Lilly Co Eli Alkilasi menurun dari gliko peptida anti biotik
US20020032216A1 (en) 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
US5994297A (en) 1997-08-22 1999-11-30 Eli Lilly And Company Therapy for Staphylococcus aureus
US6518242B1 (en) 1998-02-20 2003-02-11 Theravance, Inc. Derivatives of glycopeptide antibacterial agents
CA2344318C (en) 1998-09-25 2006-07-04 Cubist Pharmaceuticals, Inc. Methods for administration of antibiotics
SI1140993T1 (en) 1998-12-23 2003-12-31 Theravance, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
HUP0200940A3 (en) 1999-05-03 2002-10-28 Lilly Co Eli Use of glycopeptide antibiotic for treatment of streptococcus pneumoniae infections and pharmaceutical compositions containing them
US6750224B1 (en) 1999-05-07 2004-06-15 Wockhardt Limited Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment
US6331550B1 (en) 1999-06-29 2001-12-18 Smithkline Beecham Corporation Methods of use of quinolone compounds against anaerobic pathogenic bacteria
US6262071B1 (en) 1999-06-29 2001-07-17 Smithkline Beecham Corporation Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria
US6803376B1 (en) 1999-06-29 2004-10-12 Smithkline Beecham Corporation Method of use of quinolone compounds against pneumococcal and haemophilus bacteria
CA2282066C (en) 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
JP2005097116A (ja) 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
US6514986B2 (en) 2000-11-22 2003-02-04 Wockhardt Limited Chiral fluoroquinolone arginine salt forms
US6444813B2 (en) 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
EP1262477B1 (en) 2000-02-09 2008-09-03 Daiichi Sankyo Company, Limited Anti-acid-fast bacterial agents containing pyridonecarboxylic acids as the active ingredient
CA2408806A1 (en) 2000-03-31 2001-10-04 Masayasu Sekiguchi Quinolonecarboxylic acid derivative
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
DE60135102D1 (de) 2000-05-02 2008-09-11 Theravance Inc Verfahren zur reduktiven alkylierung von glykopeptiden
AU2001259306A1 (en) 2000-05-02 2001-11-12 Advanced Medicine, Inc. Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
US6608078B2 (en) 2000-05-08 2003-08-19 Wockhardt Limited Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
HUP0301562A2 (hu) 2000-06-05 2003-12-29 Dong A Pharm. Co., Ltd. Új oxazolidinonszármazékok és eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények
DE60133198T2 (de) 2000-06-22 2009-03-12 Theravance, Inc., South San Francisco Glykopeptidderivate mit carboxysacchariden
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
ATE544745T1 (de) 2000-07-07 2012-02-15 Tufts College 9-substituierte minocyclinverbindungen
JP2002201191A (ja) 2000-09-28 2002-07-16 Dai Ichi Seiyaku Co Ltd キノロンカルボン酸誘導体の製造方法およびその製造中間体
ZA200303558B (en) 2000-11-24 2004-09-06 Meiji Seika Kaisha Novel carbapenem derivatives.
JP2002255962A (ja) 2001-02-26 2002-09-11 Dai Ichi Seiyaku Co Ltd キノロンカルボン酸誘導体
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
US7045507B2 (en) 2001-03-14 2006-05-16 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
CA2444899C (en) 2001-04-24 2011-06-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US6589955B2 (en) 2001-06-20 2003-07-08 Bristol-Myers Squibb Company Pediatric formulation of gatifloxacin
EP2332548A1 (en) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of stroke
TWI275594B (en) 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
JP2003096075A (ja) 2001-09-26 2003-04-03 Dai Ichi Seiyaku Co Ltd キノロンカルボン酸誘導体の製法
WO2003076428A1 (fr) 2002-03-08 2003-09-18 Daiichi Pharmaceutical Co., Ltd. Derive d'acide quinolone-carboxylique
EP1482926A4 (en) 2002-03-08 2006-04-12 Paratek Pharm Innc AMINO METHYL SUBSTITUTED TETRACYCLINE COMPOUNDS
DE10210779A1 (de) 2002-03-12 2003-10-09 Merck Patent Gmbh Cyclische Amide
US6878686B2 (en) 2002-05-24 2005-04-12 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2003099815A1 (en) 2002-05-28 2003-12-04 Wockhardt Limited Crystalline fluoroquinolone arginine salt form
EP2277504A1 (en) 2002-10-24 2011-01-26 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
WO2004038000A2 (en) 2002-10-24 2004-05-06 Paratek Pharmaceuticals, Inc. Methods of using substituted tetracycline compounds to modulate rna
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
WO2004045637A1 (en) 2002-11-18 2004-06-03 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US7524951B2 (en) 2002-12-13 2009-04-28 Meiji Seika Kaisha, Ltd. Intermediates of 2-substituted carbapenem derivatives and process for production thereof
US6936651B2 (en) 2002-12-17 2005-08-30 E. I. Du Pont De Nemours And Company Compatibility improvement in crystalline thermoplastics with mineral fillers
JP2006151808A (ja) 2002-12-24 2006-06-15 Dai Ichi Seiyaku Co Ltd 抗菌性水性製剤
WO2004064728A2 (en) 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy
JP2004244380A (ja) 2003-02-14 2004-09-02 Dai Ichi Seiyaku Co Ltd キノロンカルボン酸の製造中間体および製造方法
WO2004091513A2 (en) 2003-04-10 2004-10-28 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
US20060270680A1 (en) 2003-06-03 2006-11-30 Goldberg Joel A Sulfonamide compounds and methods of making and using the same
ES2393292T3 (es) 2003-06-03 2012-12-20 Rib-X Pharmaceuticals, Inc. Compuestos heterocíclicos de biarilo y métodos de obtención y uso de los mismos
WO2005012271A2 (en) 2003-07-29 2005-02-10 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
US20050137174A1 (en) 2003-07-09 2005-06-23 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
JP2007500707A (ja) 2003-07-29 2007-01-18 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリールヘテロ環状のアミン、アミドおよび硫黄−含有化合物、並びに該化合物の製造方法および使用方法
WO2005061468A1 (en) 2003-12-17 2005-07-07 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
EP1778653A1 (en) 2004-07-28 2007-05-02 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic compounds and methods of making and using the same
EP2816033A1 (en) 2004-07-30 2014-12-24 Abbvie Inc. Preparation of pyridonecarboxylic acid antibacterials
PT3056492T (pt) 2004-10-08 2021-12-27 Abbvie Inc Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina)
CA2603783C (en) 2005-04-11 2014-11-18 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
US20070238719A1 (en) 2005-05-10 2007-10-11 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
US20070249577A1 (en) 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
AU2009314072C1 (en) 2008-11-15 2016-11-10 Melinta Subsidiary Corp. Antimicrobial compositions
WO2010096551A2 (en) 2009-02-18 2010-08-26 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions
US20110281839A1 (en) 2010-05-17 2011-11-17 Peterson Janet Combination therapy for the treatment of bacterial infections

Also Published As

Publication number Publication date
KR20150133762A (ko) 2015-11-30
AU2019200483A1 (en) 2019-02-14
JP6617097B2 (ja) 2019-12-04
US20160058750A1 (en) 2016-03-03
BR112015023044A2 (pt) 2017-07-18
AU2014239965A1 (en) 2015-09-24
MX2015011760A (es) 2016-06-10
HK1219690A1 (zh) 2017-04-13
US20240165100A1 (en) 2024-05-23
US12036219B2 (en) 2024-07-16
TW201513862A (zh) 2015-04-16
US20220257584A1 (en) 2022-08-18
EP2969004A1 (en) 2016-01-20
CL2015002759A1 (es) 2016-04-22
EP2969004A4 (en) 2016-09-21
KR102237887B1 (ko) 2021-04-07
CA2904387A1 (en) 2014-09-25
IL241113A0 (en) 2015-11-30
JP2016513689A (ja) 2016-05-16
BR112015023044A8 (pt) 2021-09-28
TWI641372B (zh) 2018-11-21
CA2904387C (en) 2021-12-07
JP2019196401A (ja) 2019-11-14
WO2014152332A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
DOP2014000043A (es) Pirimidinas anilladas sustituidas y uso de las mismas
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
AR089993A1 (es) Macrociclos peptidomimeticos
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
AR101740A1 (es) Terapia de combinación y composiciones
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
EA201690964A1 (ru) Композиции и способы для уменьшения серьезных неблагоприятных сердечно-сосудистых явлений
CL2015002346A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
UY33993A (es) Análogo macrocíclico de la sangliferina y su método de producción
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
UY35610A (es) Derivados de prodroga de triazolpiridinas sustituidas
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
EA201790220A1 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
AR098614A1 (es) Compuesto para el tratamiento de hipoglicemia severa

Legal Events

Date Code Title Description
FB Suspension of granting procedure